In 2025, Palantir Technologies Inc. ($PLTR) has experienced substantial insider selling activity, with insiders offloading approximately $382 million worth of shares while purchasing only about $1.2 million. This pattern has drawn comparisons to insider behavior seen in Moderna ($MRNA) during the COVID-19 years. Despite a strong broader market rally, Palantir's stock has weakened, with notable declines observed alongside other stocks such as Hims & Hers Health ($HIMS). Market participants have noted a large volume of call options at the $130 strike price for Palantir, including a significant block purchase of January 1250 $200 calls at $8.60, suggesting complex trading strategies like closing short call buy writes. The insider selling has raised questions about the company's near-term outlook, especially in light of speculation about potential sales by major stakeholders such as Peter Thiel. However, some market observers emphasize that insiders typically sell shares for various reasons but buy shares only when they anticipate price appreciation.